Biomarkers in ADHD — Can a Blood Test Diagnose It?
Dopamine metabolites, neuroinflammation, genetic panels, and salivary cortisol tests — the state of biomarker research in ADHD diagnosis.
What Is a Biomarker and Why Are We Looking for One in ADHD?
A biomarker (biological marker) is an objective indicator that measures and evaluates a normal or pathological process in the body, or a response to a therapeutic intervention. Blood pressure is a biomarker for cardiac health, and blood sugar is a biomarker for diabetes.
Currently, ADHD diagnosis is based on clinical interviews, behavioral rating scales, developmental history, and DSM-5 diagnostic criteria. This situation makes the diagnostic process dependent on the clinician's experience and the patient's (or family's) subjective reporting.
An objective biomarker (such as a simple blood or urine test) could:
Completely eliminate societal biases like labeling individuals as "lazy" or "spoiled."
Prevent diagnostic delays or misdiagnoses (gaslighting) frequently experienced by women and adults.
Base medication selection on direct biological data rather than a trial-and-error approach.
However, finding a single, clear biological marker in complex neurodevelopmental conditions like ADHD remains one of neuroscience's biggest and most challenging goals.
---
Dopamine Metabolites and Urine/Blood Tests
Since ADHD is known to be associated with deficiencies in the dopaminergic system, early research focused on dopamine and norepinephrine metabolites (breakdown products) in blood and urine.
HVA and MHPG measurement: Homovanillic Acid (HVA), the breakdown product of dopamine, and MHPG, the breakdown product of norepinephrine, can be measured in urine and blood samples. Early researchers hypothesized that children with ADHD would show lower levels of these compounds in their urine.
Why aren't they used clinically?:
1. The Blood-Brain Barrier: Dopamine levels measured in the body (plasma or urine) do not directly reflect dopamine activity in critical brain regions like the prefrontal cortex or striatum. Peripheral dopamine is largely produced by the digestive system and kidneys.
2. Overlap and Variation: There is massive overlap between the values of ADHD individuals and neurotypical controls. Test results lack the sensitivity required to make a diagnosis at the individual level.
Therefore, urine tests like "dopamine level tests" sold online or in certain laboratories are medically and scientifically invalid for diagnosing ADHD.
---
Neuroinflammation, Cytokines, and the Gut-Brain Axis
In recent years, ADHD research has focused heavily on low-grade chronic inflammation and immune system activation.
Cytokine assays: Research shows that individuals with ADHD tend to have higher average levels of certain pro-inflammatory cytokines, such as Interleukin-6 (IL-6) and TNF-alpha, in blood tests compared to neurotypical controls.
The Gut-Brain Axis: Alterations in the gut microbiota (dysbiosis) are thought to increase intestinal permeability, triggering systemic inflammation. This inflammation can cross the blood-brain barrier and activate microglial cells in the brain (neuroinflammation), negatively impacting attention and motivation networks.
Limitation: Inflammation is not specific to ADHD. Similar cytokine elevations are seen in many different psychiatric and neurological conditions, including depression, anxiety, autism, and schizophrenia. Therefore, cytokines cannot serve as a differential diagnostic tool, though they are valuable as general indicators of systemic state.
---
Genetic Panels and microRNA Technology
The revolution in molecular biology and genetics has pushed the search for ADHD biomarkers to the level of gene expression and epigenetics.
microRNA (miRNA) analysis: microRNAs are small RNA molecules that regulate how genes produce proteins. miRNA analysis in saliva or blood samples shows that the expression of certain miRNAs associated with brain development and neuroplasticity differs in individuals with ADHD. This field is one of the promising candidates that could assist in clinical diagnosis in the future.
Polygenic Risk Scoring (PRS): Calculating a cumulative score of risk variants in an individual's DNA using large-scale GWAS data. PRS does not provide an "ADHD diagnosis"; instead, it statistically indicates how high a biological predisposition the individual carries.
Commercial Gene Tests: Commercially marketed genetic panels claiming to tell you "which ADHD medication you should use from a simple saliva sample" do not yet have sufficient scientific evidence for standard clinical use. These tests do not offer a definitive prescription; they merely provide the physician with a minor probability map.
The Future Diagnostic Model: Scientists predict that diagnosis in the future will not be made with a single test, but with a "holistic biopsychosocial" model combining genetic risk scores, fMRI brain network analysis, miRNA profiles, and clinical interviews integrated through artificial intelligence.